GENESIS CABRERA: Open Payments
NPI 1255063343 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,792 in 117 payments from 14 companies in 2025. Trend: 2023 $3,690 · 2024 $1,779 · 2025 $2,792
Food & beverage: $2,705Education: $87
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 20 | $621 |
| ABBVIE INC. | 22 | $405 |
| Lilly USA, LLC | 14 | $346 |
| LEO Pharma Inc. | 17 | $260 |
| Incyte Corporation | 6 | $241 |
| Arcutis Biotherapeutics, Inc. | 10 | $225 |
| PFIZER INC. | 8 | $170 |
| Janssen Biotech, Inc. | 7 | $169 |
| Galderma Laboratories, L.P. | 5 | $117 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $96 |
Products named: DUPIXENT, RINVOQ, OPZELURA, Zoryve, TALTZ, TREMFYA, ADBRY, SKYRIZI.
Industry payments across NY — which companies pay providers there.
